Age Related Macular Degeneration, Diabetic Retinopathy
Conditions
Keywords
intraocular pressure, bevacizumab, acetazolamide, brimonidine, anterior chamber paracentesis
Brief summary
The purpose of this study is to evaluate the effects of anterior chamber paracentesis, brimonidine and oral acetazolamide to reduce intra-ocular pressure variations after intravitreal bevacizumab injection.
Interventions
DRUGAcetazolamide
250 mg 1 hour before intravitreal injection
DRUGBrimonidine tartarate
1 drop 1 hour before intravitreal injection
PROCEDUREAnterior chamber paracentesis
Immediately after bevacizumab injection
Sponsors
Fundação de Apoio ao Ensino Pesquisa e Assitência do HCFMRPUSP
University of Sao Paulo
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of age related macular disease or diabetic retinopathy * Able and willing to provide informed consent
Exclusion criteria
* History of ocular hypertension or glaucoma * High Myopes (\> 6 spherical diopters) * High Hyperopes (\> 4 spherical diopters) * Pulmonary disease * Renal disease * Known allergy to any component of the study drug * Myocardial infarction, transient ischemic attack within 4 months prior to randomization or any contraindication for bevacizumab use
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intraocular pressure (mmHg) | 1 hour and, 3 minutes before IVI. 3,10,20, 30 minutes after IVI |
Outcome results
None listed